Articles by George Judea

James Frates Joins Amylyx Pharmaceuticals as Chief Financial Officer January 14, 2021

– Former Alkermes Chief Financial Officer Expands Amylyx Executive Leadership Team as the Company Grows and Scales Amylyx Pharmaceuticals, Inc., a pharmaceutical company focused on developing new treatments for amyotrophic lateral sclerosis (ALS), Alzheimer’s Disease and other neurodegenerative diseases, today announced the appointment of James Frates as Chief Financial Officer (CFO), effective Jan. 25, 2021. Mr. Frates joins Amylyx following his tenure as CFO at Alkermes, since 1998. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210114005141/en/ James Frates, Amylyx Chief Financial Officer (Photo: Business Wire) “We are so excited for Jim to join us at this critical juncture for Amylyx,” said Joshua Cohen, Co-CEO, Chairman and Co-Founder of Amylyx. “Jim’s depth and breadth of experience as a biopharmaceutical executive coupled with his financial acumen and personal mission for bringing promising treatments to patients

Read More

Stay Connected

Get the latest news and updates from Amylyx, delivered right to your inbox.

By clicking SUBMIT, you confirm that you have read Amylyx's Privacy Policy and that you agree to receive the electronic communications from Amylyx that you've selected. You can withdraw your consent at any time.

Stay Connected

Get the latest news and updates from Amylyx, delivered right to your inbox.

By clicking SUBMIT, you confirm that you have read Amylyx's Privacy Policy and that you agree to receive the electronic communications from Amylyx that you've selected. You can withdraw your consent at any time.